 |
|
|
| |
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry
|
| |
| |
EASL 2022 June 22-26 London
CH. HUNG1, TS. CHANG2, CF. HUANG3, HT. KUO4, CC. LO5, CW. HUANG6, LW. CHONG7,8, PN. CHENG9, ML. YEH3,10, CY. PENG11,12, CY. CHENG13, JF. HUANG3,14, MJ. BAIR15,16, CL. LIN17, CC. YANG18, SJ. WANG19, TY. HSIEH20, TH. LEE21, PL. LEE22, WC. WU23, CL. LIN24, WW. SU25, SS. YANG26, CC. WANG27, JT. HU28, LR. MO29, CT. CHEN20,30, YH. HUANG31,32, CC. CHANG33,34, CS. HUANG35, GY. CHEN36, CN. KAO37, CM. TAI38,39, CJ. LIU40, MH. LEE41, PC. TSAI3, CY. DAI3, JH. KAO40, HC. LIN31,32, WL. CHUANG3, CY. CHEN42, KC. TSENG43,44, ML. YU3
|
| |
|
|
|
|
|
